Skip to main content

Advertisement

SpringerLink
Log in

Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Continuous infusion (CI) of beta-lactams could optimize their pharmacokinetic/pharmacodynamic indices, especially in difficult-to-treat infections.

Purpose

To validate an easy-to-use method to guide beta-lactams dosage in CI (formula).

Methods

A retrospective analysis was conducted of a prospectively collected cohort (n = 24 patients) with osteoarticular infections caused by Gram-negative bacilli (GNB) managed with beta-lactams in CI. Beta-lactams dose was calculated using a described formula (daily dose = 24 h × beta-lactam clearance × target “steady-state” concentration) to achieve concentrations above the MIC. We correlated the predicted concentration (Cpred = daily dose/24 h × beta-lactam clearance) with the patient’s observed concentration (Cobs) measured by UPLC–MS/MS (Spearman’s coefficient).

Results

The most frequent microorganism treated was P. aeruginosa (21 cases; 9 MDR). Beta-lactams in CI were ceftazidime (n = 14), aztreonam (7), and piperacillin/tazobactam (3), mainly used in combination (12 with colistin, 5 with ciprofloxacin) and administered without notable side effects. The plasma Cobs was higher overall than Cpred; the Spearman correlation between both concentrations was rho = 0.6 (IC 95%: 0.2–0.8) for all beta-lactams, and rho = 0.8 (IC 95%: 0.4–1) for those treated with ceftazidime.

Conclusions

The formula may be useful in clinical practice for planning the initial dosage of beta-lactams in CI, while we await a systematic therapeutic drug monitoring. The use of beta-lactams in CI was safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.

    Article  CAS  PubMed  Google Scholar 

  2. Eagle H, Fleischman R, Musselman AD. Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med. 1950;9:280–99.

    Article  CAS  PubMed  Google Scholar 

  3. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of “bug and drug”. Nat Rev Microbiol. 2004;2:289–300.

    Article  CAS  PubMed  Google Scholar 

  4. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–47.

    Article  CAS  PubMed  Google Scholar 

  5. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.

    Article  CAS  PubMed  Google Scholar 

  6. Van Herendael B, Jeurissen A, Tulkens PM, Vlieghe E, Verbrugghe W, Jorens PG, et al. Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin. Ann Intensive Care. 2012;2:22.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mohd Hafiz A-A, Staatz CE, Kirkpatrick CMJ, Lipman J, Roberts JA. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol. 2012;78:94–104.

    PubMed  Google Scholar 

  8. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care. 2005;13:598–606.

    Article  Google Scholar 

  9. Alou L. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother. 2005;55:209–13.

    Article  CAS  PubMed  Google Scholar 

  10. Cappelletty DM, Kang SL, Palmer SM, Rybak MJ. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;39:1797–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5–15.

    Article  CAS  PubMed  Google Scholar 

  12. Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56:236–44.

    Article  CAS  PubMed  Google Scholar 

  13. Roberts JA, Abdul-Aziz M-H, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681–91.

    Article  CAS  PubMed  Google Scholar 

  14. Gilbert P, Collier PJ, Brown MR. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother. 1990;34:1865–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gilbert P, Brown MR. Biofilms and beta-lactam activity. J Antimicrob Chemother. 1998;41:571–2.

    Article  CAS  PubMed  Google Scholar 

  16. Ribera A, Benavent E, Lora-Tamayo J, Tubau F, Pedrero S, Cabo X, et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams. J Antimicrob Chemother. 2015;70:3357–65.

    CAS  PubMed  Google Scholar 

  17. Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010;44:929–35.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70:3178–83.

    CAS  PubMed  Google Scholar 

  19. Georges B, Conil J-M, Seguin T, Ruiz S, Minville V, Cougot P, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother. 2009;53:4483–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.

    Article  CAS  PubMed  Google Scholar 

  22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

    Article  CAS  PubMed  Google Scholar 

  23. Xu H, Zhou W, Zhou D, Li J, Al-Huniti N. Evaluation of aztreonam dosing regimens in patients with normal and impaired renal function: a population pharmacokinetic modeling and monte carlo simulation analysis. J Clin Pharmacol. 2017;57:336–44.

    Article  CAS  PubMed  Google Scholar 

  24. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010;6:1017–31.

    Article  CAS  PubMed  Google Scholar 

  25. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009;43:1324–37.

    Article  CAS  PubMed  Google Scholar 

  26. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med. 2009;37:2071–8.

    Article  CAS  PubMed  Google Scholar 

  27. Rigo-Bonnin R, Cobo-Sacristán S, Padullés A, Ribera A, Arbiol-Roca A, Murillo Ó, et al. Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections. Biomed Chromatogr. 2016;30:410–8.

    Article  CAS  PubMed  Google Scholar 

  28. Rigo-Bonnin R, Ribera A, Arbiol-Roca A, Cobo-Sacristán S, Padullés A, Murillo Ò, et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of β-lactam antibiotic concentration in human plasma. Clin Chim Acta. 2017;468:215–24.

    Article  CAS  PubMed  Google Scholar 

  29. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30:11–8.

    Article  CAS  PubMed  Google Scholar 

  30. Hoiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015;21:S1–25.

    Article  PubMed  Google Scholar 

  31. Klinger-Strobel M, Stein C, Forstner C, Makarewicz O, Pletz M. Effects of colistin on biofilm matrices of Escherichia coli and Staphylococcus aureus. Int J Antimicrob Agents. 2017;49:472–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Michael Maudsley for helping with the English in this manuscript.

Funding

This work was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by the European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015). A. R. was supported by a research grant from the Bellvitge Biomedical Research Institute (IDIBELL).

Author information

Authors and Affiliations

  1. Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain

    Alba Ribera, Laura Soldevila, Joan Gómez-Junyent, Javier Ariza & Oscar Murillo

  2. Clinical Laboratory Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain

    Raul Rigo-Bonnin

  3. Microbiology Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain

    Fe Tubau

  4. Ciber de Enfermedades Respiratorias ISCIII, Madrid, Spain

    Fe Tubau

  5. Pharmacy Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain

    Ariadna Padullés

Authors
  1. Alba Ribera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Soldevila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raul Rigo-Bonnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fe Tubau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ariadna Padullés
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joan Gómez-Junyent
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Javier Ariza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Oscar Murillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oscar Murillo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and informed consent

The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The approval was obtained from Hospital Universitari de Bellvitge Ethics Committee, a tertiary-care hospital (Barcelona).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ribera, A., Soldevila, L., Rigo-Bonnin, R. et al. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use. Infection 46, 239–244 (2018). https://doi.org/10.1007/s15010-018-1116-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-018-1116-6

Keywords

Search

Navigation